Agomab Therapeutics NV
AGMBDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AGMB-129 | Phase 2 | Fibrostenotic Crohn's Disease | - | - |
Frequently asked questions
What is in Agomab Therapeutics NV's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Agomab Therapeutics NV's (AGMB) pipeline across Phase 2. Its lead program is AGMB-129 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Agomab Therapeutics NV's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Agomab Therapeutics NV (AGMB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AGMB biotech catalysts?→
Add AGMB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Agomab Therapeutics NV's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.